Communications BiologyCell BiologyPeer-reviewed journal article
Adhirons are efficient tools to guide antiviral ligand discovery
Alex J. FlynniD, Alex DerryiD, Oliver J. Debski-AntoniakiD, Stephen P. MuenchiD, Juan FontanaiD, Katie J. SimmonsiD
Abstract
Adhirons are small, antibody-like proteins expressed in bacteria that bind to biological targets with high affinity. Since their discovery, Adhirons have been isolated against over 350 targets, and they can be used for many research applications. However, their therapeutic application is at present in its early stages, hence the interest in developing novel small molecules to mimic their effect. We developed a pipeline for small molecule discovery where Adhirons act as starting templates in a ligand-based virtual screening workflow. For proof of concept, we used Adhirons against two viral systems: Crimean-Congo Haemorrhagic Fever Virus and Influenza A Virus. In both cases, a hit was identified from the mimics using biophysical and cell-based assays, highlighting how Adhirons, commercial libraries and structural approaches can be combined to accelerate small molecule inhibitor discovery of viruses.
- organism: virus
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 1
- FWCI
- 0.51
- Field percentile
- top 31%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In silico discovery and biological validation of ligands of FAD synthase, a promising new antimicrobial target
I. Lans, E. Anoz-Carbonell, … P. Cossio·PLOS Computational BiologyPeer-reviewed·Aug 14, 2020
- High-content image-based drug screen identifies a clinical compound against cell transmission of adenovirus
F. Georgi, F. Kuttler, … U. F. Greber·bioRxiv·Mar 24, 2020
- Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
T. Ginez, U. Garaigorta, … C. Gil·bioRxiv·Nov 26, 2020
- AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 Inhibitors
Domiziana Cecchini, AkshatKumar Nigam, … Christoph Gorgulla·bioRxiv·Apr 25, 2023
- A new concept in antiviral drug design yields a potent influenza inhibitor
C. Mackenzie-Kludas, W.-Y. Wu, … L. E. Brown·bioRxiv·Nov 8, 2022
- In-silico Structural and Molecular Docking-Based Drug Discovery Against Viral Protein (VP40) of Marburg Virus: A Causative Agent of MAVD
Sameer Quazi, Tanya Golani, … Z Haider·bioRxiv·Jan 26, 2021